Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
Ward
John F
JF
Nevada Cancer Institute, Las Vegas, NV 89135, USA. jward@nvcancer.org
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D017322:Clinical Trials, Phase II as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen